Continuous renal replacement therapy with oXiris® in patients with hematologically malignant septic shock: A retrospective study

Table 1 Description of the patients included in the two groups, n (%)

	oXiris® group (n = 26)	CRRT group (n = 19)	χ2	P value
Management before			0.309f	1
HSCT	69.23 (18)	68.42 (13)
Chemotherapy	23.08 (6)	19.23 (5)
CAR-T	7.69 (2)	5.26 (1)
Source of infection			4.218f	0.592
Positive blood culture	50 (13)	63.15 (12)
Severe pneumonia	30.77 (8)	26.32 (5)
Liver abscess	7.69 (2)
Severe acute pancreatitis	7.69 (2)
Splenic abscess	3.85 (1)	5.26 (1)
Skin soft tissue infection		5.26 (1)
Respiratory support			0.002	0.964
Invasive ventilation	73.08 (19)	73.6 (14)
HFNC or face mask	26.92 (7)	26.4 (5)
APACHE II	26.5 (20.75, 32.25)	29.5 (22.0, 31.25)	-0.431z	0.667
Outcome
ICU stay (d)	9.5 (5.75, 22.5)	10.5 (6.5, 24.0)	0z	1
Mortality (%)	34.60	57.80	2.409	0.121

^fFisher’s exact test.

^zMann–Whitney U test.

APACHE II: Acute physiology and chronic health evaluation II score; CAR-T: Chimeric antigen receptor T-cell immunotherapy; HSCT: Hematopoietic stem cell transplantation; ICU: Intensive care unit.

Table 2 Continuous renal replacement therapy treatment condition, n (%)

0.530 (χ2)	oXiris® group (n = 26)	CRRT group (n = 19)	χ2	P value
CRRT			0.530	0.467
CVVH	18 (69.2)	15 (78.9)
CVVHDF	8 (30.8)	4 (21.1)
citrate	96.15 (25)	100	0.747f	1
No anticoagulation	3.65 (1)	0	0.747f	1
Time between ICU admission and initiation of blood	5 (3, 21.25)	15 (3, 22)	-0.761z	0.447
Total CRRT hours	58 (48, 88.5)	86 (39, 122)	-0.726z	0.468
Sessions	2 (1, 2)	2 (1, 3)	-1.141z	0.254

^fFisher’s exact test.

^zMann–Whitney U test.

CRRT: continuous renal replacement therapy; CVVH: Continuous venovenous hemodiafiltration; CVVHDF: Continuous venovenous hemodiafiltration; ICU: Intensive care unit.

Table 3 Proportion of negative balance of the two groups on d3 and d4, n (%)

	oXiris® group (n = 26)	CRRT group (n = 19)	χ2	P value
d3	12/26 (46.2)	5/19 (26.3)	1.838	0.175
d4	15/26 (57.7)	5/19 (26.3)	4.377	0.036a

^aIndicates statistically significant difference compared with the control group (P < 0.05).

CRRT: Continuous renal replacement therapy; d3 and d4, days 3 and 4.

Table 4 Perfusion computed tomography and blood cytokine levels in the oXiris^® group

	d0	d3	d7
PCT (ng/mL)	15 ± 21	14 ± 23	3 ± 5a
IL-6 (pg/mL)	2871 ± 2063	32 ± 16a	9 ± 7a
TNF-α (pg/mL)	12 ± 10	2 ± 1.8a	0.3 ± 0.4a

^aIndicates a statistically significant difference compared with the 0 day (P < 0.05).

PCT: Perfusion computed tomography; IL-6: Interleukin 6; TNF-α: Tumor necrosis factor .